Avadel Pharmaceuticals (AVDL) EBT (2016 - 2021)
Historic EBT for Avadel Pharmaceuticals (AVDL) over the last 13 years, with Q4 2021 value amounting to -$23.1 million.
- Avadel Pharmaceuticals' EBT fell 34672.72% to -$23.1 million in Q4 2021 from the same period last year, while for Dec 2021 it was -$88.2 million, marking a year-over-year decrease of 237958.13%. This contributed to the annual value of -$85.5 million for FY2021, which is 36416.71% down from last year.
- Latest data reveals that Avadel Pharmaceuticals reported EBT of -$23.1 million as of Q4 2021, which was down 34672.72% from -$25.7 million recorded in Q3 2021.
- Avadel Pharmaceuticals' 5-year EBT high stood at $36.3 million for Q2 2017, and its period low was -$78.4 million during Q4 2018.
- Over the past 5 years, Avadel Pharmaceuticals' median EBT value was -$11.9 million (recorded in 2019), while the average stood at -$9.3 million.
- Its EBT has fluctuated over the past 5 years, first skyrocketed by 264712.92% in 2017, then tumbled by 127868.45% in 2018.
- Quarter analysis of 5 years shows Avadel Pharmaceuticals' EBT stood at -$5.7 million in 2017, then tumbled by 1278.68% to -$78.4 million in 2018, then surged by 30.43% to -$54.5 million in 2019, then surged by 90.5% to -$5.2 million in 2020, then plummeted by 346.73% to -$23.1 million in 2021.
- Its EBT stands at -$23.1 million for Q4 2021, versus -$25.7 million for Q3 2021 and -$23.3 million for Q2 2021.